254 related articles for article (PubMed ID: 20353291)
1. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.
Riviere K; Huang Z; Jerger K; Macaraeg N; Szoka FC
J Drug Target; 2011 Jan; 19(1):14-24. PubMed ID: 20353291
[TBL] [Abstract][Full Text] [Related]
2. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model.
Pan XQ; Wang H; Lee RJ
Pharm Res; 2003 Mar; 20(3):417-22. PubMed ID: 12669962
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a folate receptor-targeted immunoglobulin G-doxorubicin conjugate.
Yang T; Xu L; Li B; Li W; Ma X; Fan L; Lee RJ; Xu C; Xiang G
Int J Nanomedicine; 2017; 12():2505-2515. PubMed ID: 28408821
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes.
Xiang G; Wu J; Lu Y; Liu Z; Lee RJ
Int J Pharm; 2008 May; 356(1-2):29-36. PubMed ID: 18258394
[TBL] [Abstract][Full Text] [Related]
7. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
8. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo.
Zhu Y; Cheng L; Cheng L; Huang F; Hu Q; Li L; Tian C; Wei L; Chen D
Pharm Res; 2014 Dec; 31(12):3289-303. PubMed ID: 24858397
[TBL] [Abstract][Full Text] [Related]
9. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
10. Isomeric folate-conjugated polymeric micelles bind to folate receptors and display anticancer effects.
Dong Q; Xie ZX; Xie C; Lu WY; Zhang Q; Li X; Liu M
Asian Pac J Cancer Prev; 2014; 15(17):7363-9. PubMed ID: 25227843
[TBL] [Abstract][Full Text] [Related]
11. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
12. Folate receptor targeted biodegradable polymeric doxorubicin micelles.
Yoo HS; Park TG
J Control Release; 2004 Apr; 96(2):273-83. PubMed ID: 15081218
[TBL] [Abstract][Full Text] [Related]
13. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
14. Surface-Modified Nanoerythrocyte Loading DOX for Targeted Liver Cancer Chemotherapy.
Wang Y; Chen X; He D; Zhou Y; Qin L
Mol Pharm; 2018 Dec; 15(12):5728-5740. PubMed ID: 30359027
[TBL] [Abstract][Full Text] [Related]
15. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
16. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor.
Kim D; Lee ES; Park K; Kwon IC; Bae YH
Pharm Res; 2008 Sep; 25(9):2074-82. PubMed ID: 18449626
[TBL] [Abstract][Full Text] [Related]
18. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antitumor effects of folate-targeted ursolic acid stealth liposome.
Yang G; Yang T; Zhang W; Lu M; Ma X; Xiang G
J Agric Food Chem; 2014 Mar; 62(10):2207-15. PubMed ID: 24528163
[TBL] [Abstract][Full Text] [Related]
20. Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay.
Zhang C; Wu Y; Dong Y; Xu H; Zhao L
Pharm Biol; 2016; 54(1):55-61. PubMed ID: 25880143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
